Ultralife Corporation cash flow to debt ratio of 22.13% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Ultralife Corporation's free cash flow has decreased 51.59% from $14.70M last year to $7.12M, signaling decreasing performance

Ultralife Corporation's debt to equity ratio is 0.36, which means that the company's assets are healthy financed, signaling financial stability.

Ultralife Corporation's debt has decreased relative to shareholder equity from 0.44 last year to 0.36 today, signaling strengthened financials

Ultralife Corporation has a net debt to EBITDA ratio of 38.24x, which exceeds the 3.00x threshold, indicating high leverage and potential financial risk

Ultralife Corporation's interest coverage ratio is 1.38, which means that the company struggles to meet interest obligations, signaling financial risk.

Ultralife Corporation's profit margin has decreased (191.14%) in the last year from 3.84% to -3.50%, signaling decreasing performance

Ultralife Corporation's short-term assets of $105.80M exceed its short-term liabilities of $37.33M

Ultralife Corporation's return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Ultralife Corporation's return on equity of -4.95%, is lower than 15.00%, indicating bad performance

Ultralife Corporation's operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Ultralife Corporation had positive net income in only 2 out of 5 years, indicating unstable earnings

Ultralife Corporation has positive free cash flow, indicating the company generates cash after capital expenditures

Ultralife Corporation has a free cash flow yield of 6.16%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

Ultralife Corporation's yearly earnings has decreased 193.44% since last year from $6.31M to $-5.90M, signaling decreasing performance

Ultralife Corporation's yearly revenue has increased 16.24% since last year from $164.46M to $191.16M, signaling increasing performance

ROIC 1.92% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Ultralife Corporation's 3-year revenue CAGR of 13.18% is positive, indicating growing revenue over the past 3 years

Ultralife Corporation had revenue growth in 4 out of 5 years, indicating consistent revenue performance

Ultralife Corporation had positive ROE in only 2 out of 5 years, indicating inconsistent returns on equity

Ultralife Corporation has insufficient data to evaluate this check.

Ultralife Corporation has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Ultralife Corporation is overvalued relative to its fair value price of 2.53 based on EBITDA multiple model

Ultralife Corporation has an EV/EBITDA ratio of 147.92x, which exceeds the 20.00x threshold, indicating the stock may be overvalued relative to its operating earnings

Ultralife Corporation is undervalued relative to its fair value price of 11.00 based on Earnings Fair Value model

Ultralife Corporation has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Ultralife Corporation has a price-to-book ratio of 0.87x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Ultralife Corporation has a price-to-sales ratio of 0.62x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue